Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) shares climbed 1.8% to $15.14, as the company announced the U.S. Food and Drug Administration accepted for review a New Drug Application for DUZALLO™ (fixed-dose combination of lesinurad and allopurinol) for the treatment of hyperuricemia in patients with uncontrolled gout. Share volume was 842,000, compared to an all-day average of 1.3 million
